An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas

M. Agulnik, J. L. Yarber, Scott Heitaka Okuno, M. von Mehren, B. D. Jovanovic, B. E. Brockstein, A. M. Evens, R. S. Benjamin

Research output: Contribution to journalArticle

165 Citations (Scopus)

Abstract

Background: To determine efficacy and safety of bevacizumab, a recombinant humanized antibody against vascular endothelial growth factor (VEGF), in the treatment of metastatic or locally advanced angiosarcoma and epithelioid hemangioendotheliomas. Patients and methods: In this single-arm phase II trial, 32 patients were enrolled and they received bevacizumab 15 mg/kg IV infusion in 21-day cycles. Patients had disease that was deemed not surgically resectable, Eastern Cooperative Oncology Group (ECOG) performance status of <1, adequate organ function and had not received any radiation treatment in the last 28 days. Results: Of the 30 patients evaluated for efficacy and toxic effect, four (two angiosarcoma and two epithelioid hemangioendothelioma; 17%) had a partial response. Fifteen patients (11 angiosarcoma and 4 epithelioid hemangioendothelioma; 50%) showed stable disease with a mean time to progression of 26 weeks. Bevacizumab was well tolerated with only one grade 4 adverse event. Expected known toxic effects of the drug were manageable. Conclusion: Bevacizumab is an effective and well-tolerated treatment for metastatic or locally advanced angiosarcoma and epithelioid hemangioendotheliomas. Further phase III studies of bevacizumab in combination with other chemotherapeutic agents and/or radiation treatment are warranted.

Original languageEnglish (US)
Article numbermds237
Pages (from-to)257-263
Number of pages7
JournalAnnals of Oncology
Volume24
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Epithelioid Hemangioendothelioma
Hemangiosarcoma
Poisons
Radiation
Therapeutics
Antibodies, Monoclonal, Humanized
Vascular Endothelial Growth Factor A
Bevacizumab
Safety
Pharmaceutical Preparations

Keywords

  • Angiosarcoma
  • Bevacizumab
  • Hemangioendotheliomas
  • Soft tissue sarcoma

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Agulnik, M., Yarber, J. L., Okuno, S. H., von Mehren, M., Jovanovic, B. D., Brockstein, B. E., ... Benjamin, R. S. (2013). An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Annals of Oncology, 24(1), 257-263. [mds237]. https://doi.org/10.1093/annonc/mds237

An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. / Agulnik, M.; Yarber, J. L.; Okuno, Scott Heitaka; von Mehren, M.; Jovanovic, B. D.; Brockstein, B. E.; Evens, A. M.; Benjamin, R. S.

In: Annals of Oncology, Vol. 24, No. 1, mds237, 01.2013, p. 257-263.

Research output: Contribution to journalArticle

Agulnik, M, Yarber, JL, Okuno, SH, von Mehren, M, Jovanovic, BD, Brockstein, BE, Evens, AM & Benjamin, RS 2013, 'An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas', Annals of Oncology, vol. 24, no. 1, mds237, pp. 257-263. https://doi.org/10.1093/annonc/mds237
Agulnik, M. ; Yarber, J. L. ; Okuno, Scott Heitaka ; von Mehren, M. ; Jovanovic, B. D. ; Brockstein, B. E. ; Evens, A. M. ; Benjamin, R. S. / An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. In: Annals of Oncology. 2013 ; Vol. 24, No. 1. pp. 257-263.
@article{317c886e085248d0a48be5c07ce1a91e,
title = "An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas",
abstract = "Background: To determine efficacy and safety of bevacizumab, a recombinant humanized antibody against vascular endothelial growth factor (VEGF), in the treatment of metastatic or locally advanced angiosarcoma and epithelioid hemangioendotheliomas. Patients and methods: In this single-arm phase II trial, 32 patients were enrolled and they received bevacizumab 15 mg/kg IV infusion in 21-day cycles. Patients had disease that was deemed not surgically resectable, Eastern Cooperative Oncology Group (ECOG) performance status of <1, adequate organ function and had not received any radiation treatment in the last 28 days. Results: Of the 30 patients evaluated for efficacy and toxic effect, four (two angiosarcoma and two epithelioid hemangioendothelioma; 17{\%}) had a partial response. Fifteen patients (11 angiosarcoma and 4 epithelioid hemangioendothelioma; 50{\%}) showed stable disease with a mean time to progression of 26 weeks. Bevacizumab was well tolerated with only one grade 4 adverse event. Expected known toxic effects of the drug were manageable. Conclusion: Bevacizumab is an effective and well-tolerated treatment for metastatic or locally advanced angiosarcoma and epithelioid hemangioendotheliomas. Further phase III studies of bevacizumab in combination with other chemotherapeutic agents and/or radiation treatment are warranted.",
keywords = "Angiosarcoma, Bevacizumab, Hemangioendotheliomas, Soft tissue sarcoma",
author = "M. Agulnik and Yarber, {J. L.} and Okuno, {Scott Heitaka} and {von Mehren}, M. and Jovanovic, {B. D.} and Brockstein, {B. E.} and Evens, {A. M.} and Benjamin, {R. S.}",
year = "2013",
month = "1",
doi = "10.1093/annonc/mds237",
language = "English (US)",
volume = "24",
pages = "257--263",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas

AU - Agulnik, M.

AU - Yarber, J. L.

AU - Okuno, Scott Heitaka

AU - von Mehren, M.

AU - Jovanovic, B. D.

AU - Brockstein, B. E.

AU - Evens, A. M.

AU - Benjamin, R. S.

PY - 2013/1

Y1 - 2013/1

N2 - Background: To determine efficacy and safety of bevacizumab, a recombinant humanized antibody against vascular endothelial growth factor (VEGF), in the treatment of metastatic or locally advanced angiosarcoma and epithelioid hemangioendotheliomas. Patients and methods: In this single-arm phase II trial, 32 patients were enrolled and they received bevacizumab 15 mg/kg IV infusion in 21-day cycles. Patients had disease that was deemed not surgically resectable, Eastern Cooperative Oncology Group (ECOG) performance status of <1, adequate organ function and had not received any radiation treatment in the last 28 days. Results: Of the 30 patients evaluated for efficacy and toxic effect, four (two angiosarcoma and two epithelioid hemangioendothelioma; 17%) had a partial response. Fifteen patients (11 angiosarcoma and 4 epithelioid hemangioendothelioma; 50%) showed stable disease with a mean time to progression of 26 weeks. Bevacizumab was well tolerated with only one grade 4 adverse event. Expected known toxic effects of the drug were manageable. Conclusion: Bevacizumab is an effective and well-tolerated treatment for metastatic or locally advanced angiosarcoma and epithelioid hemangioendotheliomas. Further phase III studies of bevacizumab in combination with other chemotherapeutic agents and/or radiation treatment are warranted.

AB - Background: To determine efficacy and safety of bevacizumab, a recombinant humanized antibody against vascular endothelial growth factor (VEGF), in the treatment of metastatic or locally advanced angiosarcoma and epithelioid hemangioendotheliomas. Patients and methods: In this single-arm phase II trial, 32 patients were enrolled and they received bevacizumab 15 mg/kg IV infusion in 21-day cycles. Patients had disease that was deemed not surgically resectable, Eastern Cooperative Oncology Group (ECOG) performance status of <1, adequate organ function and had not received any radiation treatment in the last 28 days. Results: Of the 30 patients evaluated for efficacy and toxic effect, four (two angiosarcoma and two epithelioid hemangioendothelioma; 17%) had a partial response. Fifteen patients (11 angiosarcoma and 4 epithelioid hemangioendothelioma; 50%) showed stable disease with a mean time to progression of 26 weeks. Bevacizumab was well tolerated with only one grade 4 adverse event. Expected known toxic effects of the drug were manageable. Conclusion: Bevacizumab is an effective and well-tolerated treatment for metastatic or locally advanced angiosarcoma and epithelioid hemangioendotheliomas. Further phase III studies of bevacizumab in combination with other chemotherapeutic agents and/or radiation treatment are warranted.

KW - Angiosarcoma

KW - Bevacizumab

KW - Hemangioendotheliomas

KW - Soft tissue sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84876506864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876506864&partnerID=8YFLogxK

U2 - 10.1093/annonc/mds237

DO - 10.1093/annonc/mds237

M3 - Article

VL - 24

SP - 257

EP - 263

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

M1 - mds237

ER -